- 全部删除
您的购物车当前为空
Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) 是一种具有口服活性、选择性和高效性的血管内皮生长因子受体 (VEGFR) 酪氨酸激酶抑制剂,抑制 VEGFR-1、VEGFR-2、VEGFR-3 ,可用于研究转移性肾细胞癌 (RCC)和乳腺癌等实体肿瘤疾病。

Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) 是一种具有口服活性、选择性和高效性的血管内皮生长因子受体 (VEGFR) 酪氨酸激酶抑制剂,抑制 VEGFR-1、VEGFR-2、VEGFR-3 ,可用于研究转移性肾细胞癌 (RCC)和乳腺癌等实体肿瘤疾病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 233 | In stock | |
| 5 mg | ¥ 538 | In stock | |
| 10 mg | ¥ 782 | In stock | |
| 25 mg | ¥ 1,280 | In stock | |
| 50 mg | ¥ 1,920 | 5日内发货 | |
| 100 mg | ¥ 2,860 | 5日内发货 | |
| 500 mg | ¥ 6,780 | 5日内发货 |
Tivozanib hydrochloride hydrate 相关产品
| 产品描述 | Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3. |
| 靶点活性 | VEGFR2:6.5 nM, VEGFR3:15 nM, VEGFR1:30 nM |
| 体外活性 | Tivozanib hydrochloride hydrate(0-100 nM;24小时)抑制了 HUVEC 细胞的增殖[1]。 |
| 体内活性 | 在 Calu-6 肿瘤携带无胸腺小鼠模型中,Tivozanib hydrochloride hydrate(0.04-1 mg/kg/day;口服,持续14-21天)能够抑制肿瘤生长、血管生成和血管通透性[1]。 |
| 别名 | KRN951 hydrochloride hydrate, AV-951 hydrochloride hydrate |
| 分子量 | 509.34 |
| 分子式 | C22H22Cl2N4O6 |
| CAS No. | 682745-41-1 |
| Smiles | O.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC |
| 存储 | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (196.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容